Novartis Korea’s Entresto, a heart failure treatment, repeatedly shows significant growth. Entresto has consistently achieved over 30% growth in sales each year since its release in October 2017, having passed six years.

Since its release, Entresto has undergone five price reductions to suppress the steep increase in prescription sales. However, as Entresto’s simultaneous reimbursement range expanded, efforts to suppress sales were ineffective.

Prescription sales of Entresto exceeds 50 billion won. The drug has shown a steep growth of more than 30% annually

IQVIA, a drug market research agency, reported on the 8th that Entresto’s outpatient prescription sa